(NASDAQ: IBIO) Ibio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.55%.
Ibio's earnings in 2026 is -$33,044,000.On average, 7 Wall Street analysts forecast IBIO's earnings for 2027 to be -$18,996,363, with the lowest IBIO earnings forecast at -$24,578,233, and the highest IBIO earnings forecast at -$12,694,252. On average, 10 Wall Street analysts forecast IBIO's earnings for 2027 to be -$27,845,042, with the lowest IBIO earnings forecast at -$53,381,453, and the highest IBIO earnings forecast at -$14,854,976.
In 2028, IBIO is forecast to generate -$38,687,245 in earnings, with the lowest earnings forecast at -$62,956,804 and the highest earnings forecast at -$17,555,881.